HROW
Harrow, Inc. Common Stock
Nasdaq · usd
Harrow, Inc. Common Stock (HROW) trades at $28.81 (-0.96%) as of 4:45:23 AM EST on Nov 17, 2026, +6.63% over the past month. Market cap is $1.09B, with 14.1 days to cover in short interest.
Stock performance
How Harrow, Inc. Common Stock (HROW) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.42%
- 1W
- +5.90%
- 1M
- +6.63%
- YTD
- -40.63%
- 1Y
- -26.78%
- 52-wk range
- $25.76 – $54.85
Key statistics
Today's trading snapshot for HROW: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $29.09
- Volume
- 0
- Market cap
- $1.09B
- Shares out
- 37.53M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Harrow, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 3.60
- P/B
- 37.41
- P/FCF
- —
- ROE
- -97.6%
- ROA
- -6.4%
- Debt/Equity
- 10.03
- Div yield
- 0.00%
As of Nov 16, 2026
8-K filings
Material corporate events Harrow, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Investor presentationNov 9, 2026
Attached as Exhibit 99.3 to this Current Report on Form 8-K is a presentation of the Company that may be used by the management of the Company in connection with its earnings call, at investor conferences, and at meetings describing the Company.
- Acquisition completionOct 5, 2026
On October 1, 2026, the Company completed the acquisition of the Acquired Assets and assumed the Assumed Liabilities (the "Closing"). At the Closing, the Company paid Viatris $30.0 million in cash, funded with cash on hand.
- Executive officer departureSep 4, 2026
Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”).
- Investor presentationAug 10, 2026
Attached as Exhibit 99.3 to this Current Report on Form 8-K is a presentation of the Company that may be used by the management of the Company in connection with its earnings call, at investor conferences, and at meetings describing the Company.
- Acquisition agreementAug 6, 2026
On August 3, 2026, Harrow, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Viatris Inc. ("Viatris"), pursuant to which the Company agreed to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg ("TYRVAYA"), a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (the "Acquisition"). As consideration for the Acquisition, the Company will pay Viatris thirty million dollars ($30,000,000) in cash at the closing of the Acquisition (the "Closing") and has agreed to pay up to an additional seventy million dollars ($70,000,000) in contingent milestone payments.
Dividend history and stock splits
Harrow, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-5Feb 8, 2013
HROW short interest
How heavily HROW is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 14.1
- Short interest
- 7.09M
- Avg volume
- 502.07K
As of · reported to FINRA twice monthly.
HROW news
The latest news and headlines about Harrow, Inc. Common Stock (HROW).
- Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to SaynegativeZacks Investment Research· Nov 9, 2026
- Harrow (HROW) Q3 Earnings Lag EstimatesnegativeZacks Investment Research· Nov 9, 2026
- Profound Medical (PROF) Reports Q3 Loss, Beats Revenue EstimatesnegativeZacks Investment Research· Nov 5, 2026
- Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleasepositiveZacks Investment Research· Nov 4, 2026
- Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?positiveZacks Investment Research· Nov 2, 2026
Frequently asked questions
What is the Harrow, Inc. Common Stock (HROW) stock price today?
Harrow, Inc. Common Stock (HROW) is trading at $28.81 (-0.96% on the day) as of 4:45:23 AM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Harrow, Inc. Common Stock?
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S.
What is the short interest in HROW?
As of Oct 30, 2026, HROW has 7.09M shares short and 14.1 days to cover.
What exchange is HROW listed on?
Harrow, Inc. Common Stock (HROW) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of HROW with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a HROW analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.